Britain to study weight loss drug's potential to get people back to work

Posted on:
Key Points

Britain is set to explore the potential of Eli Lilly's weight loss drug to improve public health and economic productivity by reducing long-term sickness...

Britain will study whether the use of Eli Lilly's weight loss drug can get people back into work and help tackle the high rate of long-term sickness that has become a major drag on the economy...

British Health Minister Wes Streeting predicted the use of the drug - a competitor to Novo Nordisk's Ozempic - could help transform the health of the nation, after Lilly announced a 279 million pound ($365 million) investment in Britain as part of a flagship summit hosted by Prime Minister Keir Starmer...

Streeting said that while the drug would be a tool to tackle obesity, people would need to make lifestyle changes too so that the state-run health service, already struggling after years of crises, was not put under further strain...

You might be interested in

Drug used to treat diabetes could help obese people lose weight: Study

27, Oct, 23

The diabetes drug Mounjaro has helped people with obesity to lose at least a quarter of their body weight, or about 60 pounds on average when combined with intensive diet and exercise, as per a new study.

Weight loss drugs transforming healthcare, may help with addiction

09, Nov, 23

A new class of weight loss drugs is transforming the U.S. healthcare system in ways that could extend to equally hard-to-treat areas like substance abuse, according to speakers at the Reuters Events Total Health conference in Chicago this week.

Roche enters obesity drugs race with $2.7 bln Carmot deal

04, Dec, 23

The race to grab a slice of the lucrative market for obesity treatments is heating up among drugmakers, with Swiss company Roche (ROG.S) becoming one of the latest entrants following its $2.7 billion deal to buy Carmot Therapeutics (CRMO.O).

India adding to its diabetes, hypertension, obesity, and hypercholesterolemia burden, says study

09, Jun, 23

Thirty-one million Indians became diabetic between 2019-2021, according to a paper touted as “one of the first comprehensive studies covering all States of India” to assess the non-communicable diseases (NCD) burden in the country.

Children with severe obesity at age 4 may have a life expectancy of just 39: Study

15, May, 24

The study included more than 10 million participants from countries around the world, approximately 2.7 million of whom were aged between 2 and 29 years.. A...

Almost half of children on the weight-loss drug semaglutide are no longer clinically obese, landmark study finds

18, May, 23

A study by Minnesota University found that 45% of children who took the jab once a week for more than a year dropped enough weight to be out of the medically-concerning range.

More evidence needed on Lilly's weight loss drug, UK watchdog says

27, Jun, 23

UK's drug cost-effectiveness watchdog on Tuesday did not recommend Eli Lilly's weight loss drug for adults with diabetes, saying more evidence was needed before it could be used by the National Health Service (NHS).

Eli Lilly's Zepbound: Here's what to know about new obesity drug approved by FDA

09, Nov, 23

The US Food and Drug Administration has approved a new obesity drug- Zepbound

Weight-loss drugs: What and for whom are they good for?

02, Jan, 24

Can weight-loss drugs treat heart and kidney diseases to conditions such as Parkinson's and alcohol addiction? What and for whom are these drugs good for? | Health